A study of angiotensin II pressor response throughout primigravid pregnancy

N. F. Gant, G. L. Daley, S. Chand, P. J. Whalley, P. C. MacDonald

Research output: Contribution to journalArticle

959 Citations (Scopus)

Abstract

The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order to define when in pregnancy resistance to the pressor effects of angiotensin II develops; to define the physiologic sequence of events leading to this resistance; and to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy induced hypertension. With this prospective approach, 2 separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy. 192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the 2 groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the 2 groups became significant (P<0.01) by 23-26 wk of pregnancy. Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91% remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90% developed pregnancy induced hypertension.

Original languageEnglish (US)
Pages (from-to)2682-2689
Number of pages8
JournalJournal of Clinical Investigation
Volume52
Issue number11
StatePublished - 1973

Fingerprint

Angiotensin II
Pregnancy
Pregnancy Induced Hypertension
Vascular Resistance
Hypertension
Blood Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gant, N. F., Daley, G. L., Chand, S., Whalley, P. J., & MacDonald, P. C. (1973). A study of angiotensin II pressor response throughout primigravid pregnancy. Journal of Clinical Investigation, 52(11), 2682-2689.

A study of angiotensin II pressor response throughout primigravid pregnancy. / Gant, N. F.; Daley, G. L.; Chand, S.; Whalley, P. J.; MacDonald, P. C.

In: Journal of Clinical Investigation, Vol. 52, No. 11, 1973, p. 2682-2689.

Research output: Contribution to journalArticle

Gant, NF, Daley, GL, Chand, S, Whalley, PJ & MacDonald, PC 1973, 'A study of angiotensin II pressor response throughout primigravid pregnancy', Journal of Clinical Investigation, vol. 52, no. 11, pp. 2682-2689.
Gant, N. F. ; Daley, G. L. ; Chand, S. ; Whalley, P. J. ; MacDonald, P. C. / A study of angiotensin II pressor response throughout primigravid pregnancy. In: Journal of Clinical Investigation. 1973 ; Vol. 52, No. 11. pp. 2682-2689.
@article{4456c66623e6480083ff22d13b4e475d,
title = "A study of angiotensin II pressor response throughout primigravid pregnancy",
abstract = "The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order to define when in pregnancy resistance to the pressor effects of angiotensin II develops; to define the physiologic sequence of events leading to this resistance; and to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy induced hypertension. With this prospective approach, 2 separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy. 192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the 2 groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the 2 groups became significant (P<0.01) by 23-26 wk of pregnancy. Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91{\%} remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90{\%} developed pregnancy induced hypertension.",
author = "Gant, {N. F.} and Daley, {G. L.} and S. Chand and Whalley, {P. J.} and MacDonald, {P. C.}",
year = "1973",
language = "English (US)",
volume = "52",
pages = "2682--2689",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - A study of angiotensin II pressor response throughout primigravid pregnancy

AU - Gant, N. F.

AU - Daley, G. L.

AU - Chand, S.

AU - Whalley, P. J.

AU - MacDonald, P. C.

PY - 1973

Y1 - 1973

N2 - The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order to define when in pregnancy resistance to the pressor effects of angiotensin II develops; to define the physiologic sequence of events leading to this resistance; and to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy induced hypertension. With this prospective approach, 2 separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy. 192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the 2 groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the 2 groups became significant (P<0.01) by 23-26 wk of pregnancy. Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91% remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90% developed pregnancy induced hypertension.

AB - The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order to define when in pregnancy resistance to the pressor effects of angiotensin II develops; to define the physiologic sequence of events leading to this resistance; and to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy induced hypertension. With this prospective approach, 2 separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy. 192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the 2 groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the 2 groups became significant (P<0.01) by 23-26 wk of pregnancy. Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91% remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90% developed pregnancy induced hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0015820627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015820627&partnerID=8YFLogxK

M3 - Article

C2 - 4355997

AN - SCOPUS:0015820627

VL - 52

SP - 2682

EP - 2689

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -